Next Article in Journal
The Economic Landscape of Global Rabies: A Scoping Review and Future Directions
Previous Article in Journal
One Health Approach to Trypanosoma cruzi: Serological and Molecular Detection in Owners and Dogs Living on Oceanic Islands and Seashore Mainland of Southern Brazil
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
TropicalMed
Volume 10
Issue 8
10.3390/tropicalmed10080221
tropicalmed-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

High Efficacy of Triclabendazole/Ivermectin Combination Compared to Triclabendazole Monotherapy for Treating Human Fascioliasis in Upper Egypt: A Prospective Study

by
Waleed Attia Hassan
1,
Haidi Karam-Allah Ramadan
1,*,
Mona Gaber
2,
Samia S. Alkhalil
3 and
Alzahraa Abdelraouf Ahmad
2
1
Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt
2
Department of Medical Parasitology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt
3
Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Alquwayiyah, Riyadh 11961, Saudi Arabia
*
Author to whom correspondence should be addressed.
Trop. Med. Infect. Dis. 2025, 10(8), 221; https://doi.org/10.3390/tropicalmed10080221
Submission received: 15 July 2025 / Revised: 1 August 2025 / Accepted: 4 August 2025 / Published: 6 August 2025
(This article belongs to the Section Neglected and Emerging Tropical Diseases)
Browse Figures
Versions Notes

Abstract

Triclabendazole (TCBZ) is the gold standard treatment for fascioliasis. However, reports on resistance are increasing, emphasizing the need for alternative therapy. Combining TCBZ with ivermectin (IVM) was found to be effective for treating animal fascioliasis. Building on this, we aimed to evaluate the efficacy of the TCBZ/IVM combination therapy for human fascioliasis. This study enrolled 136 patients with Fasciola from Upper Egypt, and they were divided into the first group (n = 65), who received TCBZ monotherapy, and the second group (n = 71), who received the TCBZ/IVM combination. Assessments were to evaluate treatment response based on clinical, eosinophilic, and radiological parameters. Chronic fasciolosis was diagnosed in 17 patients (12.5%). No differences were observed in age and sex. Significant improvements were noted in all parameters in both groups, with more pronounced effects observed in the second group. A significantly higher complete response, including clinical, eosinophilic, and radiological improvements, was reported in the combined therapy group, with 53.3% compared to 26.2% in the monotherapy group (p < 0.001). A high baseline eosinophilic count was significantly associated with response. The efficacy of the TCBZ/IVM combination for treating human fascioliasis suggested a possible boosting effect, which can benefit regions of TCBZ failure. Further large-scale randomized studies are warranted to confirm these findings.

1. Introduction

Fascioliasis is a significant zoonotic disease caused by liver flukes of the genus Fasciola, specifically Fasciola hepatica, Fasciola gigantica, or both of them as a hybrid infection. The disease affects both humans and livestock worldwide, with approximately 17 million individuals affected across 81 different countries [1]. Fascioliasis has been prioritized by the World Health Organization (WHO) in its roadmap for addressing Neglected Tropical Diseases (NTDs) by 2030 [2]. The disease is presented in two clinical phases: acute and chronic phases, whereas the chronic phase is associated with biliary obstruction and fibrosis [3].
Fascioliasis is prevalent in areas with extensive agricultural and livestock farming practices, where people are often exposed to raw vegetables containing the encysted metacercaria. Notably, the prevalence of this condition has been reported in Bolivia, Peru, Cuba, China, Iran, Vietnam, and Egypt [4]. In Egypt, both F. hepatica and F. gigantica coexist, and F. hepatica is the more prevalent species found in humans, while both species have been retrieved from various animal species [5,6]. In the past few decades, fascioliasis has been recognized as an endemic disease with a re-emerging condition in Upper Egypt [7,8]. Human cases range from mild to severe, particularly in the Nile Delta region [9]. Meanwhile, Upper Egypt experiences fewer cases, but they are rising because of climate change [10].
Triclabendazole, a derivative of benzimidazole, has been recognized as the standard treatment for fascioliasis because of its effectiveness in targeting both immature and adult flukes [11]. Several reports of TCBZ resistance and treatment failures in humans have also been published, raising concerns about the long-term utility of TCBZ [7,12,13,14,15]. These challenges have driven the search for alternative or adjunctive treatments to improve treatment effectiveness and overcome resistance.
Ivermectin (IVM) is an effective broad-spectrum antiparasitic agent, exhibiting significant efficacy against various helminths and ectoparasites through a distinct mechanism of action that differs from TCBZ, which targets the nervous and muscular systems of helminths [16,17,18]. IVM has demonstrated safety and efficacy in treating various nematode infections, including onchocerciasis, strongyloidiasis, and enterobiasis, at doses of 150–200 μg/kg, and lymphatic filariasis at 400 μg/kg [19]. Although IVM is not fully effective against trematodes, it was tested in combination therapies as a trial to broaden the activity spectrum of other anthelmintics [20].
In veterinary medicine, the use of a combination of drugs is a common approach to managing parasitic infections in livestock, providing several benefits over single-drug treatments, such as targeting mixed infections involving nematodes, flukes, and even ectoparasites [21]. TCBZ is commonly marketed along with other anthelmintics, including levamisole (LEV), oxfendazole (OXF), ivermectin (IVM), abamectin, and moxidectin (MOX). These combinations can have additive or synergistic effects, allowing for lower drug concentrations, thus reducing environmental impact and selection pressure for resistance [21,22]. Furthermore, drug combinations can improve pharmacokinetics and pharmacodynamics, extend the effective lifespan of the drugs involved, enhance drug bioavailability, and potentially delay the onset of drug resistance [22,23,24].
Based on preliminary findings from in vitro and in vivo animal studies, IVM demonstrates potential as a promising candidate in a combination therapy approach for controlling fascioliasis. Notably, a synergistic effect exceeding a 27% increase in ovicidal activity was observed against F. hepatica eggs when IVM was combined with other treatments [25]. Furthermore, combination therapies incorporating IVM, such as those with TCBZ [26] or closantel [27], have exhibited effectiveness in managing animal fascioliasis [25]. Combining IVM and TCBZ showed a synergistic value through utilizing distinct mechanisms of action, where TCBZ impairs nutrient absorption and damages the parasite’s tegument, while IVM induces worm paralysis by targeting chloride channels in nerves and muscles [28,29]. This synergy may improve drug efficacy and reduce resistance risk by targeting parasites through multiple pathways simultaneously [30]. Additionally, a previous study demonstrated that IVM modulates P-glycoprotein activity, reducing TCBZ efflux from resistant flukes. Consequently, higher TCBZ concentrations were recovered from the resistant liver flukes when IVM was present [31].
This raises the question of the potential efficacy of this drug combination for treating human fascioliasis, which has not been previously explored. Establishing the safety profile, dosing guidelines for IVM in human parasitic diseases, such as strongyloidiasis, lymphatic filariasis, and scabies [32], and pharmacological efficacy observed in animal studies have suggested its potential use in treating fascioliasis, especially in areas where resistance to TCBZ or treatment failure is challenging. Therefore, this study aimed to address a gap in the literature by evaluating the effectiveness of TCBZ/IVM combination therapy for treating human fascioliasis.

2. Methods

2.1. Patient Recruitment and Diagnosis

This study was an open-label, nonrandomized prospective study conducted at the outpatient clinic of Al-Rajhy Liver University Hospital in Assiut, Upper Egypt, between June 2023 and August 2024. This hospital is situated in Assiut Governorate, in Upper Egypt, and serves numerous nearby governorates as a major tertiary hospital. Patients included in this study met the case definition for fascioliasis infection [33] and were residents of the Fasciola endemic region in Assiut Governorate, in Upper Egypt, which is located on the Nile’s west bank. It is mainly a rural community where farming is the primary occupation, with high reliance on agriculture and livestock. Participants with fascioliasis were enrolled in the study, but those with evidence of other parasitic infections or who had previously received other anti-parasitic medications, or subjects with known hypersensitivity to any of the tested medications, were excluded.
The diagnosis of fascioliasis was based on three key parameters: clinical evaluation and laboratory and/or radiological findings. The clinical manifestations included fever, right hypochondrial or epigastric pain, nausea, vomiting, jaundice, dark-colored urine, or itching. Laboratory assessment included detection of positive anti-Fasciola antibodies, elevated eosinophil levels (>6%), and/or the detection of Fasciola eggs on stool microscopy. Radiological diagnosis included the detection of hepatic focal lesions (HFLs) on abdominal ultrasound or computed tomography scans. These lesions result from the migration of juvenile flukes through liver tissue, causing localized inflammation, necrosis, and fibrosis. Bile duct abnormalities, such as duct dilatation and crescent-shaped structures, may also be evident [34].
Laboratory tests were conducted on all recruited patients, including complete blood count (CBC), including eosinophil percentage and absolute eosinophil count; liver enzymes; and stool examinations (involving direct smear and formal-ether concentration methods) to detect Fasciola eggs and exclude other parasitic infections [35]. A serological analysis was conducted using the Indirect Hemagglutination Assay (IHA) with a Distomatose Fumouze IHT kit (Fumouze Diagnostic Laboratories, Levallois-Perret, France). Anti-Fasciola antibody titers were measured, with a titer of 1:320 considered positive for comparison.

2.2. Treatment Regimens and Follow-Up

The recruited patients were categorized into two cohorts; the first group received TCBZ monotherapy, while the second group received a combination therapy of TCBZ and IVM. TCBZ was administered according to the WHO protocol as a double dose of 10 mg/kg per dose, 12 h apart with a fatty meal (Egaten, Novartis Pharma AG, Basel, Switzerland) [11]. IVM was administered at a single dose of 200 µg/kg, consistent with the dosages used for treating human nematode infections, such as strongyloidiasis, lymphatic filariasis, and scabies [18]. Newly diagnosed patients were enrolled consecutively throughout the study period. Treatments were distributed randomly among the patients. Both TCBZ and IVM were administered under direct observation to ensure adherence to the treatment protocol. Follow-up was performed after two months of receiving therapy to evaluate the cure response based on clinical improvement, eosinophil response, and radiological findings. According to the WHO, the persistence of clinical manifestations, along with either high eosinophilia (>6% in peripheral blood) or HFLs, is considered an indicator of treatment failure with TCBZ [11].

2.3. Statistical Analysis

It was performed using SPSS (version 21). For categorical data, frequency distributions and percentages were calculated, whereas quantitative variables were presented using mean ± standard deviation or median (interquartile range; IQR), contingent upon the data distribution. Comparisons between categorical variables were conducted using the chi-square or Fisher’s exact test based on sample size and expected frequencies. Quantitative variables were compared between the two groups using the independent samples t-test and Mann–Whitney U test. The Wilcoxon signed-rank and McNemar test were used to analyze within-group comparisons of data before and after treatment. To identify factors associated with therapeutic response, multivariate regression analysis was performed. A p-value of less than 0.05 was considered statistically significant.

3. Results

3.1. Characteristics of the Study Population

A total of 136 patients were enrolled in the study; 65 patients received TCBZ monotherapy, and 71 patients received a combination of TCBZ and IVM. As shown in Table 1, the baseline characteristics of the participants demonstrated no significant differences between the two groups in terms of gender, age, or residence. The study population was predominantly female (n = 77, 56.6%) and from rural areas (n = 100, 73.5%). The mean anti-Fasciola antibody titer was notably higher in the TCBZ monotherapy group (960 ± 396). The median duration of symptoms was 17 (20) days. Chronic fascioliasis was diagnosed in 17 cases (12.5%) based on the identification of Fasciola ova in stool samples and the detection of adult worms, causing biliary obstruction in the biliary channels through imaging techniques.

3.2. Clinical, Laboratory, and Radiological Data of the Participants

Significant improvements were observed in all evaluated parameters in both treatment groups, except for the presence of Fasciola ova in stool samples, which showed no notable difference between the groups. Clinically, fever and abdominal pain were reduced following treatment. Regarding laboratory findings, the liver enzymes, median white blood cell (WBC) count, eosinophil count, and percentages showed significant improvement. Radiological assessments showed that HFLs were present in 25 patients in the monotherapy group and in 41 patients in the combination therapy group (Figure 1 and Figure 2). After the treatment, using the same modality and clinician to reduce test variability, a significant reduction in the percentages of HFLs was observed in both groups. In the monotherapy group, the number of HFLs decreased from 25 to 8, whereas in the combination therapy group, it decreased from 41 to 6 (Table 2).

3.3. Evaluation of Treatment Response

As depicted in Table 3, the study findings indicate that after two months of patient follow-up, there was a significant improvement in all evaluated parameters—clinical, eosinophilic, and radiological—in both cohort groups. The combined therapy group exhibited a more pronounced positive effect with statistically significant differences. A complete response, defined as simultaneous improvement in all three parameters within the same patient, was reported in 40 out of 71 patients (53.3%) in the combined therapy group compared with only 17 patients (26.2%) in the monotherapy group (p < 0.001). In the combined therapy group, two cases developed mild itching, and ten cases had transient mild nausea and epigastric pain.

3.4. Factors Associated with Treatment Response

The analysis of factors associated with a complete response in patients treated with TCBZ monotherapy and combined TCBZ + IVM therapy showed that the most notable finding was the significant association between a high eosinophil count at baseline and a complete response (p = 0.009; OR = 1). This suggests that patients with higher eosinophil counts at the start of treatment are more likely to achieve a complete response. However, the type of treatment (TCBZ monotherapy vs. TCBZ + IVM) did not significantly affect the complete response (p = 0.168; OR = 1.860) (Table 4). Other variables such as age, gender, residence, duration of symptoms, and presence of HFL at baseline did not significantly influence the complete response.

4. Discussion

TCBZ has been the standard therapy and control of fascioliasis in several countries, including Egypt, since 1998 [11]. It exerts its action on both early immature and adult Fasciola flukes and disrupts microtubule formation and energy metabolism [36]. Despite its effectiveness, there are increasing reports of growing resistance to TCBZ in Fasciola populations, which has resulted in treatment failures in both livestock and humans [7,15,37].
In this study, the recruited patients were mostly female and predominantly from rural areas. This reflects demographic patterns commonly observed in fascioliasis-endemic regions, consistent with previous studies in Egypt [9,38,39,40]. The median duration of symptoms was 17 days, and the mean Fasciola antibody titer at baseline was consistent with the acute to subacute presentation of the disease [41]. Most reported cases were in the acute phase of the disease, whereas chronic fascioliasis was diagnosed in only 12.5% of cases, which is consistent with previous studies conducted in the same region [42].
The results of this study provide valuable insights into the effectiveness of combining TCBZ and IVM for treating human fascioliasis in Upper Egypt. The findings indicate a significant improvement in clinical, laboratory, and radiological findings in the combination therapy group. Patients who received combined therapy showed a significant increase in each of these parameters, along with higher rates of complete responses. These encouraging results suggest that combination therapy could play a crucial role in addressing TCBZ resistance and enhancing overall treatment outcomes.
The significant improvements observed in fever, abdominal pain, and ascites, along with the reduction in HFLs, underscore the effectiveness of both treatment regimens in managing the disease. Additionally, the decreases in liver enzyme levels, WBC counts, eosinophil counts, and percentages support this effectiveness. These findings align with previously reported results highlighting the efficacy of TCBZ in reducing the laboratory parameters and imaging profile of fascioliasis infection [43].
TCBZ effectively eliminates the parasite, which in turn reduces inflammation, tissue damage, and the mechanical harm caused by the migration and presence of flukes in the liver and biliary system. TCBZ functions by inhibiting the polymerization of tubulin in the parasite’s cytoskeleton, disrupting cellular division and energy metabolism, ultimately leading to the parasite’s death [36,44]. This mechanism of action allows TCBZ to target both the immature and adult stages of the parasite, making it particularly effective for treating both acute and chronic fascioliasis [11].
Our findings demonstrate that TCBZ monotherapy achieved a complete cure in only 26.2% (17/65) of patients after two months, whereas 73.8% (48/65) showed no therapeutic response. In comparison, the combination therapy group exhibited a significantly higher cure rate of 53.3%, suggesting potential treatment inefficacy of TCBZ alone under these conditions. This is in concordance with a recent study, which compared the TCBZ/IVM combination with other drugs and reported a percentage of efficacy regarding egg reduction to be 98.8% [45].
In line with our results, Hien et al. reported similarly low cure rates of 36% for TCBZ monotherapy, assessed through various outcome measures, including clinical, laboratory, and imaging parameters [33]. Additionally, Terashima et al. noted that fascioliasis failed to respond to standard-of-care (SOC) doses of TCBZ in 21 out of 27 patients who had not responded to at least two doses of TCBZ at a dosage of 10 mg/kg [46]. This situation underscores the known challenges in the management of fascioliasis, particularly regarding persistent inflammation (eosinophilia) and tissue damage associated with the disease [43]. In contrast, previous studies conducted in Egypt and other countries have reported higher response rates to TCBZ, ranging from 69% to 96%. These discrepancies may be attributable to variations in diagnostic criteria or disease stage, whether acute or chronic fascioliasis, or differences in biotype/genetics of the flukes [47,48,49].
TCBZ is commonly co-administered with other anthelmintics in veterinary practice to produce adjunctive or synergistic effects, allowing for reduced dosages, improving drug bioavailability, and prolonging treatment efficacy [21,22,23]. IVM is a broad-spectrum macrolactone that is not commonly used to treat fascioliasis because it is primarily effective against nematodes and ectoparasites. However, IVM was previously used in combination with other medications, such as TCBZ, albendazole, nitroxynil, clorsulon, and closantel, for the treatment of liver fluke infections in cattle and demonstrated remarkable effects [50].
A previous report demonstrated that combined IVM and TCBZ therapy in cattle and sheep significantly reduces Fasciola infestations [26]. A previous clinical trial in sheep found that co-administration of these compounds improves their pharmacokinetic properties, and higher peak plasma concentrations of TCBZ metabolites were detected after the co-administration of TCBZ and IVM compared to those obtained following TCBZ treatment in isolation [51]. Moreover, another study reported that the ivermectin-induced modulation of P-glycoprotein activity decreased TCBZ efflux from the resistant liver flukes, and higher concentrations of TCBZ were recovered from the resistant liver flukes in the presence of ivermectin [31].
IVM modulates the immune response, owing to its anti-inflammatory properties, in addition to its ability to promote healing [52]. It can reduce the production of pro-inflammatory cytokines, particularly Th2 cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), as well as interleukin-5 (IL-5), which is a key factor in the production of eosinophils [53]. This reduction may help decrease tissue damage, which could explain the significant improvements observed in clinical outcomes, eosinophil levels, and radiological indicators within the combined therapy group in the current study.
There are only a few reports of the direct effects of IVM on adult Fasciola species [54]. Recent research by Romero-Neto and colleagues demonstrated the ovicidal activity of IVM in vitro against F. hepatica eggs when used in combination with diaryl dichalcogenides [25]. In addition, IVM has been identified as a potential regulator of P-glycoprotein (P-gp), suggesting its important role in combating multidrug resistance. As a result, some researchers are suggesting the proactive use of IVM to help mitigate the development of resistance over time [21,31,55].
Eosinophilia is a hallmark of parasitic infections, including fascioliasis, and reflects the host’s immune response to the parasite [4]. This elevation can benefit the host during Fasciola infection by reducing IL-10 production by specific CD4+ T cells and enhancing eosinophil degranulation triggered by specific antibodies [56]. Prior research indicated that the eosinophil count serves not only as a marker for parasitic infections and underscores the immune system’s effectiveness in fighting the illness but also serves as a predictor of a positive treatment outcome [34].
In this study, patients with high eosinophil counts at the beginning of treatment were more likely to achieve complete recovery. This was demonstrated through regression analyses that examined the relationship between treatment response indicators and complete responses. The significant association between high baseline eosinophil counts and complete recovery (p < 0.001) was a key finding of the study. The observed correlation implies that individuals with stronger immune responses may experience improved treatment results, likely because of better parasite elimination. This further reinforces the therapeutic benefits of combining TCBZ and IVM. This finding is especially important and is consistent with earlier studies [7,57].
This study demonstrated promising results for treating fascioliasis by combining TCBZ and IVM, achieving high cure rates. However, several limitations were identified. The small sample size is one of these limitations; however, the disease has a seasonal pattern in the studied area, with difficulty in recruiting large numbers over a longer duration. Additionally, there is a lack of parasitological response, like egg counts, likely due to the disease’s acute nature in most cases. The study was conducted at a single center, which limits the generalizability of the findings. There was also a lack of pharmacokinetic data for the TCBZ and IVM combination to study adequately if there is a synergistic effect. In addition, the study did not include a treatment group for IVM monotherapy. However, the use of IVN monotherapy may raise ethical concerns, as no randomized trials have currently proved the efficacy of IVM in treating human fascioliasis. Therefore, the non-randomized design and small sample size highlight the need for larger, randomized trials to confirm these findings and explore the benefits of combination therapy or IVM monotherapy in diverse patient populations. Future research should focus on longer follow-up periods, multicenter studies to assess resistance patterns, evaluation of the viability of ova shed following combination therapy, and cost-effectiveness evaluations.

5. Conclusions

TCBZ is the primary treatment for fascioliasis according to the WHO, but growing resistance and low cure rates prompt the need for alternative therapies. This study provides a promising result of the efficacy of combined TCBZ and IVM for treating fascioliasis in humans, suggesting a possible boosting effect in areas of high TCBZ failure. Combination therapy showed significantly better results, with a complete response rate of 53.3%, compared with 26.2% for TCBZ monotherapy. These effects were evident in clinical, laboratory, and radiological parameters, including improvements in eosinophil counts and hepatic lesions. Further larger randomized trials will be required to confirm these findings and explore the benefits of combination therapy in diverse patient populations.

Author Contributions

Methodology, W.A.H., H.K.-A.R., M.G. and A.A.A.; data curation, W.A.H. and H.K.-A.R.; formal analysis, S.S.A.; formal analysis, writing the original draft, H.K.-A.R., M.G. and A.A.A.; conceptualization and supervision, A.A.A.; writing—review and editing, S.S.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Ethical approval for this study was obtained from the Ethical Committee of the Faculty of Medicine at Assiut University (IRB no: 17300805, date of approval: September 2022). The research was conducted in strict adherence to the principles outlined in the Helsinki Declaration.

Informed Consent Statement

Prior to participation, all enrolled patients provided a written informed consent.

Data Availability Statement

The data presented in this study are available from the corresponding author on reasonable request due to the ethical concern of patients’ privacy.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

TCBZTriclabendazole
IVMIvermectin
NTDsNeglected tropical diseases
WHOWorld Health Organization
HFLHepatic focal lesion

References

  1. Fürst, T.; Duthaler, U.; Sripa, B.; Utzinger, J.; Keiser, J. Trematode infections: Liver and lung flukes. Infect. Dis. Clin. N. Am. 2012, 26, 399–419. [Google Scholar] [CrossRef]
  2. PAHO. Operational Guidelines for the Elimination of Human Fascioliasis as a Public Health Problem in the Americas; World Health Organization. Pan American Health Organization: Washington, DC, USA, 2024; Available online: https://www.who.int/publications/i/item/9789275128084 (accessed on 20 July 2025).
  3. Mas-Coma, S. Human fascioliasis emergence risks in developed countries: From individual patients and small epidemics to climate and global change impacts. Enferm. Infecc. Microbiol. Clin. (Engl. Ed.) 2020, 38, 253–256. [Google Scholar] [CrossRef]
  4. Mas-Coma, S.; Valero, M.A.; Bargues, M.D. Fascioliasis. Digenetic Trematodes. 2019, 71–103. [Google Scholar]
  5. Lotfy, W.; El-Morshedy, H.; Abou El-Hoda, M.; El-Tawila, M.; Omar, E.; Farag, H. Identification of the Egyptian species of Fasciola. Vet. Parasitol. 2002, 103, 323–332. [Google Scholar] [CrossRef] [PubMed]
  6. Khalafala, R.E. Prevalence and phylogenetic analysis of Fasciola species in upper Egypt based on ribosomal ITS-2 gene sequencing. Egyp. Vet. Med. Soc. Parasitol. J. 2020, 16, 142–158. [Google Scholar] [CrossRef]
  7. Ramadan, H.K.-A.; Hassan, W.A.; Elossily, N.A.; Ahmad, A.A.; Mohamed, A.A.; Abd-Elkader, A.S.; Abdelsalam, E.M.N.; Khojah, H.M. Evaluation of nitazoxanide treatment following triclabendazole failure in an outbreak of human fascioliasis in Upper Egypt. PLoS Neglected Trop. Dis. 2019, 13, e0007779. [Google Scholar] [CrossRef]
  8. Ahmad, A.A.; Ramadan, H.K.-A.; Hassan, W.A.; Hakami, M.A.; Huseein, E.A.M.; Mohamed, S.A.-A.; Mohamed, A.A.; Elossily, N.A. New perspectives for fascioliasis in Upper Egypt’s new endemic region: Sociodemographic characteristics and phylogenetic analysis of Fasciola in humans, animals, and lymnaeid vectors. PLoS Neglected Trop. Dis. 2022, 16, e0011000. [Google Scholar] [CrossRef]
  9. Periago, M.V.; Valero, M.A.; Artigas, P.; Agramunt, V.H.; Bargues, M.D.; Curtale, F.; Mas-Coma, S. Very high fascioliasis intensities in schoolchildren from Nile Delta Governorates, Egypt: The Old World highest burdens found in lowlands. J. Pathog. 2021, 10, 1210. [Google Scholar] [CrossRef]
  10. Zanaty, N.; Ibrahim, N.; Ramadan, H.K.-A.; Ahmad, A.A.; Saad-Hussein, A. Significance of climate change in the emergence of human fascioliasis in Upper Egypt. Trop. Dis. Travel Med. Vaccines 2024, 10, 24. [Google Scholar] [CrossRef]
  11. WHO. Report of the WHO Informal Meeting on Use of Triclabendazole in Fascioliasis Control: WHO Headquarters, Geneva, Switzerland 17–18 October 2006; World Health Organization: Geneva, Switzerland, 2007. [Google Scholar]
  12. Ortiz, P.; Cabrera, M.; Jave, J.; Claxton, J.; Williams, D. Human fascioliasis: Prevalence and treatment in a rural area of Peru. Infect. Dis. Rev. 2000, 2, 42–46. [Google Scholar]
  13. Winkelhagen, A.J.; Mank, T.; de Vries, P.J.; Soetekouw, R. Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands. Emerg. Infect. Dis. 2012, 18, 1028. [Google Scholar] [CrossRef]
  14. Cabada, M.M.; Lopez, M.; Cruz, M.; Delgado, J.R.; Hill, V.; White, A.C., Jr. Treatment failure after multiple courses of triclabendazole among patients with fascioliasis in Cusco, Peru: A case series. PLoS Neglected Trop. Dis. 2016, 10, e0004361. [Google Scholar] [CrossRef]
  15. Kelley, J.M.; Elliott, T.P.; Beddoe, T.; Anderson, G.; Skuce, P.; Spithill, T.W. Current threat of triclabendazole resistance in Fasciola hepatica. Trends Parasitol. 2016, 32, 458–469. [Google Scholar] [CrossRef]
  16. Crump, A.; Omura, S. Ivermectin, ‘wonder drug’ from Japan: The human use perspective. Proc. Jpn. Acad. Ser. B 2011, 87, 13–28. [Google Scholar] [CrossRef]
  17. Laing, R.; Gillan, V.; Devaney, E. Ivermectin–old drug, new tricks? Trends Parasitol. 2017, 33, 463–472. [Google Scholar] [CrossRef]
  18. Sulik, M.; Antoszczak, M.; Huczyński, A.; Steverding, D. Antiparasitic activity of ivermectin: Four decades of research into a “wonder drug”. Eur. J. Med. Chem. 2023, 261, 115838. [Google Scholar] [CrossRef] [PubMed]
  19. Juarez, M.; Schcolnik-Cabrera, A.; Dueñas-Gonzalez, A. The multitargeted drug ivermectin: From an antiparasitic agent to a repositioned cancer drug. Am. J. Cancer Res. 2018, 8, 317. [Google Scholar] [PubMed]
  20. Ico-Gómez, R.; González-Garduño, R.; Ortiz-Pérez, D.; Mosqueda-Gualito, J.J.; Flores-Santiago, E.d.J.; Sosa-Pérez, G.; Salazar-Tapia, A.A. Assessment of anthelmintic effectiveness to control Fasciola hepatica and paramphistome mixed infection in cattle in the humid tropics of Mexico. Parasitology 2021, 148, 1458–1466. [Google Scholar] [CrossRef]
  21. Fairweather, I.; Brennan, G.; Hanna, R.; Robinson, M.; Skuce, P. Drug resistance in liver flukes. Int. J. Parasitol. 2020, 12, 39–59. [Google Scholar] [CrossRef]
  22. Bartram, D.J.; Leathwick, D.M.; Taylor, M.A.; Geurden, T.; Maeder, S.J. The role of combination anthelmintic formulations in the sustainable control of sheep nematodes. Vet. Parasitol. 2012, 186, 151–158. [Google Scholar] [CrossRef] [PubMed]
  23. Lanusse, C.; Lifschitz, A.; Alvarez, L. Basic and clinical pharmacology contribution to extend anthelmintic molecules lifespan. Vet. Parasitol. 2015, 212, 35–46. [Google Scholar] [CrossRef] [PubMed]
  24. Geary, T.G.; Sakanari, J.A.; Caffrey, C.R. Anthelmintic drug discovery: Into the future. J. Parasitol. 2015, 101, 125–133. [Google Scholar] [CrossRef]
  25. Romero-Neto, I.; de Almeida, T.M.; Zugman, T.; Piovan, L.; Molento, M.B. Ovicidal activity of diaryl dichalcogenides and ivermectin on Fasciola hepatica: A novel candidate for a blending-based therapeutic strategy. Acta Trop. 2024, 258, 107363. [Google Scholar] [CrossRef]
  26. Stevenson, C.; Mahoney, R.; Fisara, P.; Strehlau, G.; Reichel, M. The efficacy of formulations of triclabendazole and ivermectin in combination against liver fluke (Fasciola hepatica) and gastro-intestinal nematodes in cattle and sheep and sucking lice species in cattle. Aust. Vet. J. 2002, 80, 698–701. [Google Scholar] [CrossRef]
  27. Hanna, R.; Cromie, L.; Taylor, S.; Couper, A. The effect of a parenteral ivermectin/closantel injection on the growth and reproductive development of early immature Fasciola hepatica in cattle. Vet. Parasitol. 2006, 142, 78–90. [Google Scholar] [CrossRef]
  28. Yates, D.M.; Wolstenholme, A.J. An ivermectin-sensitive glutamate-gated chloride channel subunit from Dirofilaria immitis. Int. J. Parasitol. 2004, 34, 1075–1081. [Google Scholar] [CrossRef]
  29. Fox, L.M. Ivermectin: Uses and impact 20 years on. Curr. Opin. Infect. Dis. 2006, 19, 588–593. [Google Scholar] [CrossRef]
  30. Barnes, E.; Dobson, R.; Barger, I. Worm control and anthelmintic resistance: Adventures with a model. Parasitol. Today 1995, 11, 56–63. [Google Scholar] [CrossRef]
  31. Mottier, L.; Alvarez, L.; Fairweather, I.; Lanusse, C. Resistance-induced changes in triclabendazole transport in Fasciola hepatica: Ivermectin reversal effect. J. Parasitol. 2006, 92, 1355–1360. [Google Scholar] [CrossRef] [PubMed]
  32. Failoc-Rojas, V.E.; Silva-Díaz, H.; Maguiña, J.L.; Rodriguez-Morales, A.J.; Díaz-Velez, C.; Apolaya-Segura, M.; Valladares-Garrido, M.J. Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru. Parasite Epidemiol. Control 2023, 23, e00320. [Google Scholar] [CrossRef] [PubMed]
  33. Hien, T.T.; Truong, N.T.; Minh, N.H.; Dat, H.D.; Dung, N.T.; Hue, N.T.; Dung, T.K.; Tuan, P.Q.; Campbell, J.I.; Farrar, J.J.; et al. A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam. Am. J. Trop. Med. Hyg. 2008, 78, 388–392. [Google Scholar] [CrossRef]
  34. Caravedo, M.A.; Cabada, M.M. Human fascioliasis: Current epidemiological status and strategies for diagnosis, treatment, and control. Res. Rep. Trop. Med. 2020, 11, 149–158. [Google Scholar] [CrossRef]
  35. WHO. Bench Aids for the Diagnosis of Intestinal Parasites. 2019. Available online: https://www.who.int/publications/i/item/9789241515344 (accessed on 20 July 2025).
  36. Sprague, D.J.; Park, S.-K.; Gramberg, S.; Bauer, L.; Rohr, C.M.; Chulkov, E.G.; Smith, E.; Scampavia, L.; Spicer, T.P.; Haeberlein, S.; et al. Target-based discovery of a broad-spectrum flukicide. Nat. Struct. Mol. Biol. 2024, 31, 1386–1393. [Google Scholar] [CrossRef] [PubMed]
  37. Morales, M.L.; Tanabe, M.B.; White, A.C., Jr.; Lopez, M.; Bascope, R.; Cabada, M.M. Triclabendazole treatment failure for Fasciola hepatica infection among preschool and school-age children, Cusco, Peru. Emerg. Infect. Dis. 2021, 27, 1850. [Google Scholar] [CrossRef]
  38. Curtale, F.; El-Wahab Hassanein, Y.A.; El Wakeel, A.; Mas-Coma, S.; Montresor, A. Distribution of human fascioliasis by age and gender among rural population in the Nile Delta, Egypt. J. Trop. Pediatr. 2003, 49, 264–268. [Google Scholar] [CrossRef] [PubMed]
  39. Curtale, F.; Mas-Coma, S.; Hassanein, Y.; Barduagni, P.; Pezzotti, P.; Savioli, L. Clinical signs and household characteristics associated with human fascioliasis among rural population in Egypt: A case-control study. Parassitologia 2003, 45, 5–11. [Google Scholar] [PubMed]
  40. Curtale, F.; Hassanein, Y.A.W.; Barduagni, P.; Yousef, M.M.; Wakeel, A.E.; Hallaj, Z.; Mas-Coma, S. Human fascioliasis infection: Gender differences within school-age children from endemic areas of the Nile Delta, Egypt. Trans. R. Soc. Trop. Med. Hyg. 2007, 101, 155–160. [Google Scholar] [CrossRef] [PubMed]
  41. Mas-Coma, S.; Valero, M.A.; Bargues, M.D. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Adv. Parasitol. 2009, 69, 41–146. [Google Scholar]
  42. Ibrahim, N.; Abdel Khalek, E.M.; Makhlouf, N.A.; Abdel-Gawad, M.; Mekky, M.; Ramadan, H.K.-A.; Abu-Elfatth, A.; El-Latif, N.A.; Hassan, M.K.; Eldeeb, R.; et al. Clinical characteristics of human fascioliasis in Egypt. Sci. Rep. 2023, 13, 16254. [Google Scholar] [CrossRef]
  43. Gandhi, P.; Schmitt, E.K.; Chen, C.-W.; Samantray, S.; Venishetty, V.K.; Hughes, D. Triclabendazole in the treatment of human fascioliasis: A review. Trans. R. Soc. Trop. Med. Hyg. 2019, 113, 797–804. [Google Scholar] [CrossRef]
  44. Keiser, J.; Engels, D.; Büscher, G.; Utzinger, J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin. Investig. Drugs 2005, 14, 1513–1526. [Google Scholar] [CrossRef]
  45. Ibarra-Velarde, F.; Flores-Ramos, M.; Cruz-Mendoza, I.; Vera-Montenegro, Y.; Hernández-Campos, A.; Leyva-Gómez, G.; Rojas-Campos, T.; Tovar-Escobar, D.; Castillo, R.; Arias-García, R.; et al. Fosfatriclaben: Effective dose determination and comparative efficacy assessment with closantel, triclabendazole+ ivermectin, triclabendazole+ albendazole in artificially infected cattle. Exp. Parasitol. 2024, 266, 108830. [Google Scholar] [CrossRef] [PubMed]
  46. Terashima, A.; Canales, M.; Maco, V.; Marcos, L.A. Observational study on the effectiveness and safety of multiple regimens of triclabendazole in human fascioliasis after failure to standard-of-care regimens. J. Glob. Antimicrob. Resist. 2021, 25, 264–267. [Google Scholar] [CrossRef]
  47. El-Morshedy, H.; Farghaly, A.; Abou-Basha, S.S.L.; Barakat, R. human fascioliasis: A community-based study. East. Mediterr. Health J. 1999, 5, 888. [Google Scholar] [CrossRef] [PubMed]
  48. Talaie, H.; Emami, H.; Yadegarinia, D.; Nava-Ocampo, A.A.; Massoud, J.; Azmoudeh, M.; Mas-Coma, S. Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis. Clin. Exp. Pharmacol. Physiol. 2004, 31, 777–782. [Google Scholar] [CrossRef]
  49. Osman, M.; Shehab, A.; Zaki, A.; Farag, H. Evaluation of two doses of triclabendazole in treatment of patients with combined schistosomiasis and fascioliasis. East. Mediterr. Health J. 2011, 17, 266–270. [Google Scholar] [CrossRef]
  50. Hutchinson, G.; Dawson, K.; Fitzgibbon, C.; Martin, P. Efficacy of an injectable combination anthelmintic (nitroxynil+clorsulon+ivermectin) against early immature Fasciola hepatica compared to triclabendazole combination flukicides given orally or topically to cattle. Vet. Parasitol. 2009, 162, 278–284. [Google Scholar] [CrossRef]
  51. Lifschitz, A.; Virkel, G.; Ballent, M.; Sallovitz, J.; Lanusse, C. Combined use of ivermectin and triclabendazole in sheep: In vitro and in vivo characterisation of their pharmacological interaction. Vet. J. 2009, 182, 261–268. [Google Scholar] [CrossRef]
  52. Kaur, B.; Blavo, C.; Parmar, M.S. Ivermectin: A multifaceted drug with a potential beyond anti-parasitic therapy. Cureus 2024, 16, e56025. [Google Scholar] [CrossRef]
  53. Zhang, X.; Song, Y.; Ci, X.; An, N.; Ju, Y.; Li, H.; Wang, X.; Han, C.; Cui, J.; Deng, X. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm. Res. 2008, 57, 524–529. [Google Scholar] [CrossRef] [PubMed]
  54. Diab, T.M.; Mansour, H.H.; Mahmoud, S.S. Fasciola gigantica: Parasitological and scanning electron microscopy study of the in vitro effects of ivermectin and/or artemether. Exp. Parasitol. 2010, 124, 279–284. [Google Scholar] [CrossRef] [PubMed]
  55. Lespine, A.; Ménez, C.; Bourguinat, C.; Prichard, R.K. P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance. Int. J. Parasitol. 2012, 2, 58–75. [Google Scholar] [CrossRef]
  56. Frigerio, S.; Da Costa, V.; Costa, M.; Festari, M.F.; Landeira, M.; Rodríguez-Zraquia, S.A.; Härtel, S.; Toledo, J.; Freire, T. Eosinophils control liver damage by modulating immune responses against Fasciola hepatica. Front. Immunol. 2020, 11, 579801. [Google Scholar] [CrossRef] [PubMed]
  57. Qureshi, A.W.; Zeb, A.; Mansoor, A.; Hayat, A.; Mas-Coma, S. Fasciola hepatica infection in children actively detected in a survey in rural areas of Mardan district, Khyber Pakhtunkhawa province, northern Pakistan. Parasitol. Int. 2019, 69, 39–46. [Google Scholar] [CrossRef] [PubMed]
Tropicalmed 10 00221 g001
Figure 1. Pattern of different hypoechoic hepatic focal lesions by ultrasound in two patients (A,B) at enrollment in the study.
Figure 1. Pattern of different hypoechoic hepatic focal lesions by ultrasound in two patients (A,B) at enrollment in the study.
Tropicalmed 10 00221 g001
Tropicalmed 10 00221 g002
Figure 2. Pattern of different hypointense hepatic focal lesions by contrast-enhanced computed tomography in two patients (A,B) at enrollment in the study.
Figure 2. Pattern of different hypointense hepatic focal lesions by contrast-enhanced computed tomography in two patients (A,B) at enrollment in the study.
Tropicalmed 10 00221 g002
Table 1. Baseline characteristics of the included patients.
Table 1. Baseline characteristics of the included patients.
ItemsTotal
n = 136
(n, %)		TCBZ
(n = 65)
(n, %)		TCBZ + IVM
(n = 71) (n, %)		p-Value
Gender:
Females77 (56.6)33 (44)44 (62)0.188
Males59 (43.4)32 (27)27 (38)
Age (years) (mean ± SD)33.6 ± 17.331.6 ± 18.235.5 ± 16.40.195
Residence:
Rural100 (73.5)46 (54)54 (76.1)0.485
Urban36 (26.5)19 (17)17 (23.9)
Chronic fascioliasis17 (12.5)9 (13.8)8 (11.3)0.650
Fasciola antibody levels (mean)890.6 ± 390.3960 ± 396827 ± 376.70.047 *
* Significant p-value.
Table 2. Comparison of clinical, radiological, and laboratory data among the treatment groups before and after treatment.
Table 2. Comparison of clinical, radiological, and laboratory data among the treatment groups before and after treatment.
ItemsBefore
TCBZ (n = 65)
(n, %)		After TCBZ
(n = 65)
(n, %)		p-ValueBefore
TCBZ + IVM
(n = 71)
(n, %)		After TCBZ + IVM
(n = 71)
(n, %)		p-Value
Fever44 (67.7)5 (7.7)0.000 *32 (45.1)0<0.001 *
Abdominal pain63 (96.9)8 (12.3)0.000 *71 (100)3 (4.2)<0.001 *
Ascites7 (10.8)00.016 *4 (5.6)00.125
HFL25 (38.5)8 (12.3)0.000 *41 (57.7)6 (8.5)<0.001 *
Presence of ova in stool6 (9.2)1 (1.5)0.0634 (5.6)1 (1.4)0.250
ALT (IU/L) (median)35 (28)30 (12)0.000 *31 (20)25 (12)<0.001 *
AST (IU/L) (median)32 (28.5)26 (12)0.000 *28 (19)22 (11)<0.001 *
WBCs cells/μL (median)10,500 (8830)8600 (3355)0.000 *10,500 (6140)7430 (3020)<0.001 *
Eosinophilic count
(median) cells/μL		3576 (5717)970 (1854.5)0.000 *3250 (6500)400 (400)<0.001 *
Eosinophilic percent
(median)		36 (29)13 (17.8)0.000 *30 (37.5)6 (6)<0.001 *
HFL: hepatic focal lesion, ALT: alanine aminotransferase, AST: aspartate aminotransferase, WBCs: white blood cells. * Significant p-value.
Table 3. Comparative analysis of response patterns between treatment groups.
Table 3. Comparative analysis of response patterns between treatment groups.
ItemsTCBZ
(n = 65)
(n, %)		TCBZ + IVM
(n = 71)
(n, %)		p-Value
Clinical response56 (86.2)68 (95.8)0.048 *
Eosinophilic response21 (32.3)50 (70.4)<0.001 *
Radiological response18 (27.7)35 (49.3)0.036 *
Complete response17 (26.2)40 (53.3)<0.001 *
* Significant p-value.
Table 4. Factors associated with complete response.
Table 4. Factors associated with complete response.
Variablesp-ValueORCI
Upper Level		CI
Lower Level
Age0.2340.9850.9611.010
Gender0.8410.9150.3822.189
Residence0.8990.9380.3512.509
Duration of symptoms0.2970.9920.9761.007
HFL at baseline0.3300.6480.2711.552
High eosinophil counts at baseline0.009 *1.0001.0001.000
Treatment type0.1681.8600.7704.494
HFL: hepatic focal lesion, * Significant p-value < 0.05.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Hassan, W.A.; Ramadan, H.K.-A.; Gaber, M.; Alkhalil, S.S.; Ahmad, A.A. High Efficacy of Triclabendazole/Ivermectin Combination Compared to Triclabendazole Monotherapy for Treating Human Fascioliasis in Upper Egypt: A Prospective Study. Trop. Med. Infect. Dis. 2025, 10, 221. https://doi.org/10.3390/tropicalmed10080221

AMA Style

Hassan WA, Ramadan HK-A, Gaber M, Alkhalil SS, Ahmad AA. High Efficacy of Triclabendazole/Ivermectin Combination Compared to Triclabendazole Monotherapy for Treating Human Fascioliasis in Upper Egypt: A Prospective Study. Tropical Medicine and Infectious Disease. 2025; 10(8):221. https://doi.org/10.3390/tropicalmed10080221

Chicago/Turabian Style

Hassan, Waleed Attia, Haidi Karam-Allah Ramadan, Mona Gaber, Samia S. Alkhalil, and Alzahraa Abdelraouf Ahmad. 2025. "High Efficacy of Triclabendazole/Ivermectin Combination Compared to Triclabendazole Monotherapy for Treating Human Fascioliasis in Upper Egypt: A Prospective Study" Tropical Medicine and Infectious Disease 10, no. 8: 221. https://doi.org/10.3390/tropicalmed10080221

APA Style

Hassan, W. A., Ramadan, H. K.-A., Gaber, M., Alkhalil, S. S., & Ahmad, A. A. (2025). High Efficacy of Triclabendazole/Ivermectin Combination Compared to Triclabendazole Monotherapy for Treating Human Fascioliasis in Upper Egypt: A Prospective Study. Tropical Medicine and Infectious Disease, 10(8), 221. https://doi.org/10.3390/tropicalmed10080221

Article Metrics

Back to TopTop